Tirzepatide molecular mass and the charge states you would expect on ESI Writing it up because I had to work it out twice and would rather nobody else did.
Tirzepatide molecular mass keeps being re-asked here and I think that is because the answer is conditional and the conditions never travel with it.
Attempting to write the conditional version down properly. Corrections welcome and expected — I would like this to end up as a maintained page rather than a fifth thread.
SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose. That is the central and legitimate criticism of the head-to-head evidence and it is worth remembering when people quote the trial.
Mass and charge states: tirzepatide is about 4813.5 Da and on an electrospray instrument you would expect to see charge states mostly in the 2+ to 4+ range, the same as semaglutide. A doubly charged species would appear at about (4813.5 + 2 × 1.008) / 2 ≈ 2408.
Correct me on the arithmetic if it is wrong; I would rather know.
The opening post is the version of this I will quote in future. One addition.
Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the published schedule is not a lower bound.
Useful. I have added it to my own notes with the date on it.
The arithmetic in post #4 is right; the assumption feeding it is the part to check.
The published pharmacokinetics show dose proportionality across the studied range, which means dose arithmetic behaves the way you would naively expect. That is not true of every compound and it is worth knowing which ones it is true of.
Distinguishing three things in the tirzepatide molecular mass discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
Gastrointestinal effects were comparable in character to the GLP-1 monoagonists across the programme. Individual reports here vary in both directions, which is what you would expect from a between-person difference rather than a between-drug one.
I would not lead a decision with this, but I would not ignore it either.
This follows post #9 rather than contradicting it.
Heart rate rises modestly across this class, tirzepatide included. It is consistent, small, and worth knowing about rather than worth alarm — and it is one of the reasons the trials monitored it explicitly.
Adding it in case it saves somebody the afternoon it cost me.
Picking up post #10: that is the part I would want checked first.
Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that the question is not settled. Some of the effect is surely the GIP component, but the trial design does not decompose it.
Worth checking against a second source before it gets quoted onward.
Right — I had this wrong and I am glad to have read it before it mattered.
Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.
I would want a second opinion before relying on that.
I had written a reply contradicting post #13 and deleted it. Here is what survived.
Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly comparable in character. Individual variation is the largest factor.
That is my reading. Someone else read the same page differently and was reasonable.
Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.
Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do.
Post #14 is right about the mechanism and I think understates the practical bit.
On identity: the monoisotopic mass is close to 4813.5 Da and the electrospray series usually shows the 3+ and 4+ states most strongly at ordinary concentrations. A report that shows only a single charge state is worth a question.
This is where my knowledge stops and I would rather mark the edge than blur it.
Coming back to post #16, because the follow-up matters more than the original answer.
The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.
I am describing what is, rather than arguing for what should be.
Adding a data point of agreement rather than a data point.
Post #16 and I disagree about the size of the effect, not about the direction.
Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.
Anyone with a larger sample, please post it.
On purity: the trailing-edge features people report on tirzepatide chromatograms are frequently deamidation products, which elute close to the main peak and are easy to integrate into it. That is a method question rather than a quality question.
The evidence for this is thinner than the way I have phrased it suggests.
The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on satiety and energy expenditure, but how much of tirzepatide's effect is that and how much is simply achieving higher receptor occupancy remains genuinely open. The mechanistic literature is active.
Confirming post #21 from a second method, which matters more than confirming it from a second person.
On purity: the trailing-edge features people report on tirzepatide chromatograms are frequently deamidation products, which elute close to the main peak and are easy to integrate into it. That is a method question rather than a quality question.
A modest claim, modestly supported.
Post #21 describes the usual case. This is about the unusual one.
Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do.
Written from notes rather than memory, which is why the numbers are specific.
Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.
The interesting part of this is the exception, and I do not understand the exception.
The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.
Answering the question post #25 raises rather than the one it answers.
Mass and charge states: tirzepatide is about 4813.5 Da and on an electrospray instrument you would expect to see charge states mostly in the 2+ to 4+ range, the same as semaglutide. A doubly charged species would appear at about (4813.5 + 2 × 1.008) / 2 ≈ 2408.
That holds under the stated conditions and I have stated them.
The arithmetic in post #29 is right; the assumption feeding it is the part to check.
Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the published schedule is not a lower bound.
Same conclusion as the reply above, reached differently, which is mildly reassuring.